In an interview with Targeted Oncology™, Statish Shah, MD, the medical director of Gettysburg Cancer Center, discusses the OneOncology partnership in more detail and how it will benefit patients. Gettysburg Cancer Center has joined OneOncology, allowing the community oncology center to expand services and clinical trial resources to its patients. Small community cancer centers play...
Partnership will Expand Cancer Care Services and Access to Clinical Trials in Central Pennsylvania Gettysburg, PA and Nashville, TN – June 21, 2021 — Gettysburg Cancer Center (GCC), with clinics in Gettysburg and Hanover, PA, will join OneOncology, the national platform for independent community oncology practices, OneOncology announced today. By joining OneOncology, Gettysburg Cancer Center...
Satish Shah, MD, Medical Director, Gettysburg Cancer Center speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. Watch Video Link to Article: http://www.globenewswire.com/news-release/2021/03/24/2198364/0/en/Theratechnologies-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-TH1902-for-Sortilin-Positive-Solid-Tumors.html Theratechnologies Inc., a biopharmaceutical company focusing on the discovery and commercialization of novel therapies, is pleased to report that the...
This news release is an announcement that the Gettysburg Cancer Center (GCC) has administered the first dose of a new, innovative cancer therapy ever given to a human being anywhere in the world. This is a testament to the dedication and hard work of the doctors and staff of GCC to ensure that Gettysburg and...
A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer, Gynecological Cancer, Colorectal cancer, and Pancreatic Cancer. Even though this study is a Phase 1 it received FDA Fast Track Approval on February 4, 2021. An excerpt from the News Release...
December 9, 2020 – Hayley Virgil Renata Ferrarotto, MD, discusses trilaciclib’s unique mechanism of action in small cell lung cancer and the data that led to its FDA designation. Trilaciclib administered prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) helped to reduce chemotherapy-induced myelosuppression and limit the need for granulocyte colony-stimulating factors...
Lisa A. Newman, Robert A. Winn and John M. Carethers DOI: 10.1158/1078-0432.CCR-20-3421 Published January 2021 Abstract Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has spread worldwide. In the United States, COVID-19 disproportionately affects racial and ethnic minorities, particularly African Americans, with an observed 2-fold higher rate for hospitalization and greater than 2-fold higher rate for death as compared with White Americans....
Knowing all you can about clinical trials can help you feel more certain when deciding whether to take part in one. The information in this section addresses many questions and concerns about clinical trials. It can help prepare you to discuss the pros and cons with your doctor and your family and decide whether being...
STUDY TITLE: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in adult patients with Advanced Non-Small Cell Lung Cancer (NSCLC) INDICATION: Treatment of malignancy associated weight loss or anorexia in patients with NSCLC. STUDY DRUG: Anamorelin...
